Condition: Head and Neck Squamous Cell Carcinoma · Oncolytic Virus · TACE · Sponsor: West China Hospital
This study evaluates H101 combined with transarterial chemoembolization (TACE) to enhance local tumor killing and immune activation while minimizing toxicity in r/m HNSCC patients.
This description comes directly from the study's public registry record.
Tao Hai · 086-18982770417 · haitao42@hotmail.com
Always discuss trial participation with your own doctor first.
| West China hospital | Chengdu, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07398664